ProCE Banner Activity

The Changing Landscape of Dyslipidemia Management: Focus on PCSK9 Inhibitors

Multimedia
Approximately 121.5 million adults in the United States have cardiovascular disease; it is the leading cause of death in this country. The earlier patients begin to follow heart healthy lifestyles and modify risk factors, the greater their reduction in overall risk. In this activity, an expert lipidologist will review the most recent American College of Cardiology/American Heart Association guidelines on dyslipidemia, covering primary prevention as well as secondary prevention in patients with clinical atherosclerotic cardiovascular disease. He will also provide guidance regarding a patient-centered approach to the management of patients with dyslipidemia, including lifestyle management and when and how to use high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors.

Released: August 31, 2019

Expiration: August 29, 2020

No longer available for credit.

Share

Faculty

Douglas Jacoby

Douglas Jacoby, MD

Associate Professor of Clinical Medicine
University of Pennsylvania Health System
Director
Penn Cardiology Preventive Care
Medical Director
Penn Presbyterian Heart and Vascular Pavilion
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Mary Knudtson

Mary Knudtson, DNSc, NP, FAAN

Associate Vice Chancellor
Student Health and Wellness
Executive Director
Student Health Services
University of California, Santa Cruz
Santa Cruz, California
Professor of Clinical Nursing
University of California, Irvine
Irvine Irvine, California

 

Provided by

Kelly testing provider text override field
ProCE Banner

Supporters

This activity was developed from a series of programs cosupported by educational grants from

AbbVie

Boehringer Ingelheim

Genentech TEXT Only

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc.

Sanofi US

Shire

Teva

Target Audience

NPs and PAs

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients who are candidates for intensified cholesterol therapy with PCSK9 inhibitors
  • Initiate therapy with a PCSK9 inhibitor in appropriate patients according to current guideline updates
  • Implement shared decision-making and patient-centered approaches to improve adherence and access to lipid-lowering therapy

Faculty Disclosure

Primary Author

Douglas Jacoby, MD

Associate Professor of Clinical Medicine
University of Pennsylvania Health System
Director
Penn Cardiology Preventive Care
Medical Director
Penn Presbyterian Heart and Vascular Pavilion
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Dr Jacoby: advisory board: Regeneron.

Mary Knudtson, DNSc, NP, FAAN

Associate Vice Chancellor
Student Health and Wellness
Executive Director
Student Health Services
University of California, Santa Cruz
Santa Cruz, California
Professor of Clinical Nursing
University of California, Irvine
Irvine Irvine, California

 

Dr Knudtson has no relevant financial relationships to disclose.

Additional Information

Program Medium

This program has been made available online.